Clinical trial NCT05879172: Electric Tubular Anastomosis in Rectal Cancer
Official title: Application of Electric Tubular Anastomotic Device in Colorectal Tumor Surgery: a Multi-center Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anastomosis
Rectal Cancer
Keywords: electric tubular anastomotic device
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2023-05-30
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Compared with traditional manual suturing, mechanical anastomosis can reduce the error caused by human factors. The electric anastomotic device can improve the automation and accuracy of anastomosis, reduce the requirements for doctors' operation, and establish a more standardized usage specification, thereby reducing the surgical complication rate and improving the quality of anastomosis. The clinical study of electric tubular anastomotic device adopts a multicenter, randomized, parallel controlled non-inferior study design, and randomly groups according to the 1:1 ratio to evaluate the clinical effectiveness and safety of electric tubular anastomotic device compared with conventional manual device.

Detailed description: Compared with traditional manual suturing, mechanical anastomosis can reduce the error caused by human factors, involving the advantages like simple operation, short operation time, fast postoperative recovery, etc. Mechanical anastomosis can also ensure the consistency and repeatability of the surgical anastomosis process. The electric anastomotic device can improve the automation and accuracy of anastomosis, reduce the requirements for doctors' operation, and establish a more standardized usage specification, thereby reducing the surgical complication rate and improving the quality of anastomosis.

The clinical study of electric tubular anastomotic device adopts a multicenter, randomized, parallel controlled non-inferior study design, and randomly groups according to the 1:1 ratio to evaluate the clinical effectiveness and safety of electric tubular anastomotic device compared with conventional manual device.

The effectiveness of the electric tubular anastomotic device was evaluated by taking the success rate of anastomosis and anastomosis-related adverse events as the main evaluation indexes, while the operation performance evaluation, operation time, anastomosis time and postoperative recovery as the secondary evaluation indicators. The safety of electric tubular anastomotic device was evaluated by adverse events, vital signs, laboratory tests, etc.

Eligibility criteria: Inclusion Criteria:

* Age: 18-80y;
* Patients with resectable rectal cancer who are scheduled to undergo Dixon surgery (definition of rectal cancer: the lower boundary of the tumor is 10 cm from the anus≤);
* The patient consents to participate in the clinical study and signs the informed consent form.

Exclusion Criteria:

* Patients with significant local or systemic severe infection;
* Acute abdomen: intestinal obstruction, peritonitis, intestinal perforation;
* Have a systemic underlying disease that has not been controlled, or is unstable; Patients with poor constitution or serious other organic diseases who cannot tolerate anesthesia and surgery;
* Women during pregnancy, perinatal and lactation;
* Patients who are mentally incapable or unable to understand the requirements of the study;
* Patients who participated in other clinical studies 6 weeks before the start of this study or at the same time;
* The life expectancy of patients with malignant tumors is less than 6 months;
* Those who are critically ill and find it difficult to make an accurate evaluation of the effectiveness and safety of the device;
* Patients with diseases who are believed not suitable to participate in this clinical study;
* Have other diseases that are against anastomosis;
* The patient is receiving hormone therapy or immunosuppressive therapy;
* Albumin\< 30g/dl.

Primary outcomes:
measure: success rate of anastomosis
timeFrame: 1 week after surgery
Secondary outcomes:
measure: time period of anastomosis
timeFrame: during the operation
measure: time period of recovery
timeFrame: 1 year after surgey
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
state: Shanghai
Study officials:
References: